FDA actions in brief.
- Published in:
- Formulary, 2009, v. 44, n. 9, p. 262
- Publication type:
- Article
Works matching DE "UNITED Therapeutics Corp."
Results: 9
1
2
Adcirca.
- Published in:
- Formulary, 2009, v. 44, n. 7, p. 195
- Publication type:
- Article
3
Pharmaceutical Philanthropy or Resisting Regulations?: WHY PHARMACEUTICAL DONATIONS DO NOT VIOLATE THE ANTI-KICKBACK STATUTE.
- Published in:
- Brooklyn Law Review, 2020, v. 85, n. 2, p. 571
- By:
- Publication type:
- Article
4
Oregovomab: Anti-CA-125 Monoclonal Antibody B43.13 – AltaRex, B43.13, MAb B43.13, Monoclonal antibody B43.13.
- Published in:
- Drugs in R&D, 2006, v. 7, n. 6, p. 379
- Publication type:
- Article
5
New drugs and dosage forms.
- Published in:
- 2009
- Publication type:
- Product Review
6
Clinical Trials Update.
- Published in:
- Advances in Pulmonary Hypertension, 2011, v. 10, n. 2, p. 137, doi. 10.21693/1933-088x-10.2.137
- By:
- Publication type:
- Article
7
AbbVie buys last available priority voucher for $350 million.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 11, p. 1120, doi. 10.1038/nbt1115-1120
- By:
- Publication type:
- Article
8
Drug pipeline: 1Q15.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 6, p. 580, doi. 10.1038/nbt.3261
- By:
- Publication type:
- Article
9
United Therapeutics granted five-year patent term extension for remodulin.
- Published in:
- Journal of Intellectual Property Rights, 2005, v. 10, n. 2, p. 1557
- Publication type:
- Article